1. mTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesia.
- Author
-
Lutz, Brianna Marie, Sam Nia, Ming Xiong, Yuan-Xiang Tao, and Bekker, Alex
- Subjects
MTOR protein ,CHRONIC pain treatment ,DRUG therapy ,OPIOIDS ,HYPERALGESIA treatment ,PUBLIC health research - Abstract
Chronic pain is a major public health problem with limited treatment options. Opioids remain a routine treatment for chronic pain, but extended exposure to opioid therapy can produce opioid tolerance and hyperalgesia. Although the mechanisms underlying chronic pain, opioid-induced tolerance, and opioid-induced hyperalgesia remain to be uncovered, mammalian target of rapamycin (mTOR) is involved in these disorders. The mTOR complex 1 and its triggered protein translation are required for the initiation and maintenance of chronic pain (including cancer pain) and opioid-induced tolerance/hyperalgesia. Given that mTOR inhibitors are FDA-approved drugs and an mTOR inhibitor is approved for the treatment of several cancers, these findings suggest that mTOR inhibitors will likely have multiple clinical benefits, including anticancer, antinociception/anti-cancer pain, and antitolerance/hyperalgesia. This paper compares the role of mTOR complex 1 in chronic pain, opioid-induced tolerance, and opioid-induced hyperalgesia. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF